Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Change in Receivables (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed Change in Receivables for 6 consecutive years, with -$173000.0 as the latest value for Q4 2025.

  • Quarterly Change in Receivables rose 64.98% to -$173000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$196000.0 through Dec 2025, up 57.21% year-over-year, with the annual reading at -$196000.0 for FY2025, 57.21% up from the prior year.
  • Change in Receivables for Q4 2025 was -$173000.0 at Caribou Biosciences, down from -$152000.0 in the prior quarter.
  • The five-year high for Change in Receivables was $2.8 million in Q2 2021, with the low at -$3.5 million in Q3 2021.
  • Average Change in Receivables over 5 years is -$148650.0, with a median of -$175000.0 recorded in 2025.
  • The sharpest move saw Change in Receivables tumbled 1012.11% in 2021, then soared 7550.0% in 2025.
  • Over 5 years, Change in Receivables stood at $575000.0 in 2021, then crashed by 184.35% to -$485000.0 in 2022, then surged by 62.06% to -$184000.0 in 2023, then tumbled by 168.48% to -$494000.0 in 2024, then surged by 64.98% to -$173000.0 in 2025.
  • According to Business Quant data, Change in Receivables over the past three periods came in at -$173000.0, -$152000.0, and $306000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.